Summary: Aetna, a CVS Health company, modified CPB 1095 covering the gemcitabine intravesical system (Inlexzo) for bladder cancer treatment, effective May 8, 2026. Here's what billing teams need to do.
Aetna updated its gemcitabine intravesical system coverage policy under CPB 1095 Aetna system. This change affects urology and oncology practices billing for Inlexzo, a drug-device combination product used in non-muscle invasive bladder cancer (NMIBC) treatment. The policy does not list specific CPT or HCPCS codes in the available data — a detail your billing team needs to address before submitting claims.
| Field | Detail |
|---|---|
| Payer | Aetna |
| Policy | Gemcitabine Intravesical System (Inlexzo) - CPB 1095 |
| Policy Code | CPB 1095 |
| Change Type | Modified |
| Effective Date | 2026-05-08 |
| Impact Level | High |
| Specialties Affected | Urology, Medical Oncology, Outpatient Infusion/Procedure Centers |
| Key Action | Confirm current billing codes, prior authorization requirements, and medical necessity documentation with Aetna before submitting claims on or after May 8, 2026 |
Aetna Gemcitabine Intravesical System Coverage Criteria and Medical Necessity Requirements 2026
The Aetna gemcitabine intravesical system coverage policy under CPB 1095 addresses Inlexzo, a sustained-release intravesical drug delivery system. Inlexzo delivers gemcitabine directly into the bladder over time using a small, flexible device placed by a urologist. The FDA approved it for adults with NMIBC — specifically papillary urothelial carcinoma — after prior treatment with BCG (Bacillus Calmette-Guérin) has failed or is not feasible.
This is a relatively new product in a space where payers are still tightening their coverage standards. Aetna's modification of this policy in May 2026 signals active scrutiny. Any claims you submit without tight medical necessity documentation are at elevated risk of denial.
Because the available policy data does not include the full text of CPB 1095, the specific medical necessity criteria Aetna requires cannot be reproduced here verbatim. What is clear from the product's clinical profile and standard payer behavior is that Aetna will almost certainly require documentation of prior BCG therapy, histologic confirmation of NMIBC, and treating physician attestation that Inlexzo is medically necessary for this patient.
Prior authorization is standard for high-cost drug-device combination products like this. Assume prior auth is required for Inlexzo under Aetna plans until you confirm otherwise in writing. Submitting without prior authorization on a product at this price point is a fast path to a claim denial.
Talk to your Aetna provider relations contact or pull the full CPB 1095 policy text directly from Aetna's clinical policy bulletin library to verify exact criteria before your effective date of May 8, 2026.
Aetna Gemcitabine Intravesical System Exclusions and Non-Covered Indications
The available policy data does not detail specific exclusions for CPB 1095. That said, standard payer exclusion patterns for intravesical therapies like Inlexzo follow predictable territory.
Aetna will likely not cover Inlexzo as a first-line treatment before BCG has been attempted. Use in muscle-invasive bladder cancer — outside of Inlexzo's FDA-approved indication — would almost certainly fall outside coverage. Off-label use in other urologic malignancies or other histologies would face the same barrier.
If you are treating a patient population where any of these scenarios applies, pull the full CPB 1095 text and loop in your compliance officer before billing. The financial exposure on a single Inlexzo claim is significant enough to justify that extra step.
Coverage Indications at a Glance
The policy data available does not provide indication-level coverage details from CPB 1095. The table below reflects what is known from the product's FDA approval and standard payer coverage patterns for products in this class. Verify all entries against the full CPB 1095 text before the effective date of May 8, 2026.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| NMIBC (papillary urothelial carcinoma) in adults after BCG failure or BCG-ineligible | Likely Covered | Not specified in available data | Prior auth almost certainly required; medical necessity documentation required |
| NMIBC as first-line therapy before BCG attempt | Likely Not Covered | Not specified in available data | Confirm in full CPB 1095 text |
| Muscle-invasive bladder cancer | Likely Not Covered | Not specified in available data | Outside FDA-approved indication |
| Off-label use in other malignancies | Likely Not Covered | Not specified in available data | Off-label use typically excluded |
Pull the actual CPB 1095 policy before treating this table as definitive. Use it as a starting checklist, not a final answer.
Aetna Gemcitabine Intravesical System Billing Guidelines and Action Items 2026
Inlexzo billing is genuinely complicated right now. This is a drug-device combination product, which means it sits in a gray zone between pharmacy billing, physician procedure billing, and potentially facility billing — depending on where the procedure is performed. The modification to CPB 1095 on May 8, 2026 makes this a live problem, not a future one.
Here are the steps your billing team should take now.
| # | Action Item |
|---|---|
| 1 | Pull the full CPB 1095 policy text from Aetna before May 8, 2026. The available data does not include full criteria or code lists. Go to Aetna's clinical policy bulletin library and download the current version. Read the effective date language carefully to understand whether any claims already in your pipeline are affected. |
| 2 | Identify the correct billing codes for Inlexzo before submitting any claims. The policy data for CPB 1095 does not list specific CPT or HCPCS codes. Inlexzo gemcitabine intravesical system billing likely involves a drug HCPCS code and a procedure code for intravesical instillation — but do not guess. Call Aetna provider services or check with your drug reimbursement resource (your GPO, specialty pharmacy partner, or the manufacturer's reimbursement support line) to confirm exact codes before May 8, 2026. |
| 3 | Confirm prior authorization requirements with Aetna for every Inlexzo case. Do this before scheduling the procedure, not after. If prior auth is required and you skip it, you own the denial. For a product at Inlexzo's price point, that is not a recoverable error. |
| 4 | Build your medical necessity documentation template now. Your records need to show BCG treatment history (or documented contraindication), histologic confirmation of NMIBC, staging, and the treating physician's rationale for Inlexzo specifically. Treating physicians need to know what to document. Update your intake and procedure note templates before the effective date. |
| 5 | Check where the procedure is being performed and bill accordingly. Inlexzo placement is an in-office or outpatient procedure. If your urologists place the device in the office, the billing path is different than if it is placed in a hospital outpatient department. Facility and physician components need separate attention. If you are unsure how this splits across your practice's settings, talk to your billing consultant before your first Inlexzo claim goes out. |
| 6 | Flag existing prior auth approvals for review. If you have patients with prior authorizations in place under the old policy, confirm those approvals are still valid under the modified CPB 1095. Payers do not always grandfather old authorizations through a policy modification. |
| 7 | Watch for the HCPCS code assignment timeline. New products sometimes receive a specific HCPCS J-code after launch. If Inlexzo does not yet have a permanent HCPCS code, you may be billing with a miscellaneous code in the interim — which requires an invoice and additional documentation to process cleanly. Confirm the current coding status and document your rationale for any miscellaneous code use. |
If your practice sees significant volume of NMIBC patients and you are planning to offer Inlexzo as a treatment option, get your billing consultant and compliance officer involved now. The combination of a new product, an actively modified coverage policy, and unconfirmed billing codes is exactly the scenario that generates avoidable denials at scale.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Gemcitabine Intravesical System Under CPB 1095
The policy data available for CPB 1095 does not list specific CPT, HCPCS, or ICD-10 codes. This is a significant gap for billing teams.
Do not invent or assume codes for Inlexzo gemcitabine intravesical system billing. Using incorrect or unsupported codes is a fast path to a claim denial — and potentially a compliance issue if the wrong code pattern becomes a pattern across your claims.
Take these steps to identify the correct codes:
- Contact Aetna provider services directly and ask for the specific billing codes they recognize under CPB 1095 for the gemcitabine intravesical system.
- Contact the Inlexzo manufacturer's reimbursement support line. Manufacturers of specialty drug-device products typically have a reimbursement hotline and billing guides. UroGen Pharma, which markets Inlexzo, has reimbursement support resources — use them.
- Check for a HCPCS J-code assignment. CMS assigns J-codes to drug products for Medicare billing. If a J-code exists for gemcitabine intravesical system, it is the anchor code for both Medicare and commercial payers who follow HCPCS conventions.
- Identify the procedure code for intravesical device placement. The drug code alone is not sufficient. There is a CPT code for the instillation or placement procedure. Confirm which code Aetna accepts.
- Identify relevant ICD-10-CM diagnosis codes. NMIBC maps to specific ICD-10 codes in the C67 range (malignant neoplasm of bladder). Your claims need the correct primary and secondary diagnosis codes to support medical necessity.
Once you have confirmed codes from Aetna and the manufacturer, update your charge capture, superbills, and order entry systems before May 8, 2026. Do not wait for your first claim to bounce back before building this out.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.